Work

Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients

Year: 2020

Type: article

Study design: Case Report

Abstract: Merkel cell carcinoma (MCC) is an aggressive skin cancer, which is about twice as likely to metastasize as compared with melanoma.1 There are 2 distinct biological pathways for developing MCC: Merkel cell polyomavirus (MCPyV)-induced and ultraviolet light-induced.2 In individuals immunosuppressed by HIV infection, the risk of developing MCC is 13-fold higher than for the general population.1 Historically, outcomes have been dismal, with a 2-year disease-specific survival rate of 0% in 1 published case series.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2020.11.020

Authors: Song Y. Park, Candice Church, Nora A. Alexander, Michi M. Shinohara, Kelly G. Paulson, Karl D. Lewis, Nancy S. Lee, Paul Nghiem

Institutions: University of Washington, Swedish Medical Center, University of Colorado Cancer Center, Kaiser Permanente, Kaiser Permanente San Diego Medical Center

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $600

Funders: Prostate Cancer Foundation, Bristol-Myers Squibb, Merck, National Institutes of Health, EMD Serono, National Cancer Institute

Awards: G1470381490, Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma, G9000160898, Cancer Center Support Grant

OpenAlex ID: W3106698077

FWCI: 0.241

Cites: 13

Cited by: 4

Related to: 10